RA
REGN icon

Ruggaard & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Ruggaard & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-354
Closed -$372K – 116
2024
Q3 		$372K Hold
354
– – 0.16% 83
2024
Q2 		$372K Buy
354
+2
+0.6% +$1.94K 0.17% 79
2024
Q1 		$339K Buy
352
+10
+3% +$9.51K 0.16% 87
2023
Q4 		$300K Sell
342
-61
-15% -$50.2K 0.16% 88
2023
Q3 		$332K Sell
403
-2
-0.5% -$1.57K 0.2% 75
2023
Q2 		$291K Hold
405
– – 0.17% 85
2023
Q1 		$333K Buy
+405
New +$305K 0.21% 69

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ruggaard & Associates's REGN Position: Q4 2024 in Review

Ruggaard & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 354 shares — an estimated $372K sold.

Ruggaard & Associates first reported a position in REGN in Q1 2023 and held it in 7 quarters. The position peaked at $372K in Q3 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Ruggaard & Associates reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Ruggaard & Associates sold 354 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $372K.
  • Ruggaard & Associates first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • Ruggaard & Associates's Regeneron Pharmaceuticals position peaked at $372K in Q3 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Ruggaard & Associates's 13F filing for Q4 2024, filed 13 Feb 2025.